Introduction
============

Meningiomata, common slow-growing intracranial tumors, originate from the derivatives between the meninges and meningeal gap of the central nervous system.[@b1-ott-10-1875],[@b2-ott-10-1875] According to the World Health Organization (WHO) grading system, grade I meningioma lesions are usually benign, whereas grade II--III meningioma lesions are mostly atypical, anaplastic, or malignant.[@b3-ott-10-1875],[@b4-ott-10-1875] Chromosomal abnormalities (chromosomes 22, 1p, 9p, 10p, 11, 14q, 15, 17, and 18q) and associated genetic variants have been reported to be associated with meningioma risk.[@b4-ott-10-1875]--[@b6-ott-10-1875] For example, mutation of the *NF2* gene is reportedly related to meningioma risk.[@b7-ott-10-1875] However, the role of various gene polymorphisms in susceptibility to meningioma remains unconfirmed.

In the present study, we aimed to analyze all the relevant publications and investigate potential functional gene polymorphisms associated with meningioma risk. Ten single-nucleotide polymorphisms (SNPs) of eight genes -- *MLLT10* rs12770228, *CASP8* rs1045485, *XRCC1* rs1799782, *XRCC1* rs25487, *MTHFR* rs1801133, *MTHFR* rs1801131, *MTRR* rs1801394, *MTR* rs1805087, *GSTM1* null/present, and *GSTT1* null/present -- were selected from 20 eligible articles to conduct our meta-analysis.

There were several previous meta-analyses for associations between meningioma risk and gene polymorphisms, including *MTHFR* rs1801133, *MTRR* rs1801394, *MTR* rs1805087, *GSTM1* null/present, and *GSTT1* null/present.[@b8-ott-10-1875]--[@b13-ott-10-1875] However, an updated meta-analysis was still required. Moreover, no previous meta-analyses have been conducted to evaluate the association between *MTHFR* rs1801131, *MLLT10* rs12770228, *CASP8* rs1045485, *XRCC1* rs1799782, rs25487 polymorphisms and meningioma risks. Our data highlighted the positive association between *MLLT10* rs12770228, *MTRR* rs1801394, *MTHFR* rs1801131, and increased meningioma risk.

Materials and methods
=====================

Information sources
-------------------

We retrieved the available articles from the online databases PubMed, Embase, Central, Web of Science, and CNKI/Wanfang in September 2016. The following search terms were used: "polymorphism, genetic" or "polymorphisms, genetic" or "genetic polymorphism" or "polymorphism (genetics)" or "genetic polymorphisms" or "polymorphism" or "variant" or "variants" or "mutation" or "mutations" or "SNP" or "single nucleotide polymorphism"; "meningioma" or "meningiomas" or "angioblastic meningiomas" or "angiomatous meningiomas" or "clear cell meningiomas" or "fibrous meningiomas" or "hemangioblastic meningiomas" or "intracranial meningiomas" or "intraventricular meningiomas" or "malignant meningiomas" or "multiple meningiomas" or "meningiomatosis" or "microcystic meningioma" or "olfactory groove meningioma" or "papillary meningioma" or "posterior fossa meningioma" or "psammomatous meningiomas" or "secretory meningioma" or "sphenoid wing meningioma" or "spinal meningioma" or "transitional meningioma" or "xanthomatous meningioma" or "benign meningiomas" or "cerebral convexity meningioma".

Eligibility criteria and data extraction
----------------------------------------

We screened and collected eligible studies based on our exclusion/inclusion criteria. The selected case-control studies had to contain genotype distributions of the case-control group. Genotype distribution in the control group had to be in line with Hardy--Weinberg equilibrium (HWE). Exclusion criteria were comments, reviews, and letters; meeting abstracts; cases, trials, or not polymorphisms; not clinical data; other genes for which the number of case-control studies on specific variants was fewer than three; other diseases; meta-analyses; and lack of usable data. Then, four investigators independently performed methodological quality assessment using the Newcastle--Ottawa scale (NOS; <http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>), and extracted the specific data, mainly genes, SNP, first author, year of publication, country, ethnicity, genotype frequencies of case-control, source of control, disease group, *P*-values of HWE test, genotyping methods, number of studies, sample size, and NOS score. NOS scores ≥7 mean a high-quality study. Emails were sent for unavailable data, and a discussion was needed for discrepancies.

Data synthesis
--------------

Stata/SE 12.0 (StataCorp, College Station, TX, USA) was utilized. *P*-values of association, summary odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were estimated via Mantel--Haenszel statistics, based on the allele, homozygote, heterozygote, dominant, and recessive models. Two-sided *P*-values less than 0.05 were interpreted as statistically different; *χ*^2^ tests were used for HWE *P*-values.

Heterogeneity analysis and publication bias
-------------------------------------------

Cochran's *Q* test and *I* [@b2-ott-10-1875] statistic were applied for assessment of potential between-study heterogeneity. *P*-values for *Q* tests \>0.1 or *I* [@b2-ott-10-1875] index \<25% indicate the existence of overall statistically significant heterogeneity and the utilization of a fixed-effect model. Otherwise, a random-effect model was used.[@b14-ott-10-1875],[@b15-ott-10-1875] To analyze the main source of homogeneity, subgroup analysis by ethnicity and sensitivity analysis were conducted. In addition, Egger's test and Begg's test were carried out to evaluate potential publication bias.[@b16-ott-10-1875]--[@b18-ott-10-1875]

Results
=======

Study selection and characteristics
-----------------------------------

To identify studies on the association between potential genetic variants and meningioma risk, five online databases (PubMed, Embase, Central, Web of Science, and CNKI/Wanfang) were searched in September 2016. A flow diagram of publication search and study screening for the meta-analysis is shown in [Figure 1](#f1-ott-10-1875){ref-type="fig"}. The PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement was followed.[@b19-ott-10-1875] A total of 4,355 potentially relevant articles were retrieved initially from the databases. After the removal of duplicated articles, 2,268 articles were excluded by screening title and abstract, with reasons shown in [Figure 1](#f1-ott-10-1875){ref-type="fig"}. A total of 35 full-text articles were assessed for eligibility, and 15 were excluded for lack of usable data. As a result, 20 articles with ten polymorphisms of eight genes met our eligibility criteria and were selected for the meta-analysis.[@b20-ott-10-1875]--[@b39-ott-10-1875] [Table 1](#t1-ott-10-1875){ref-type="table"} summarizes the characteristics of the articles included. NOS scores of all the studies were larger than or equal to 7, which indicated high quality. No significant deviation from HWE was found for any of the studies. The SNPs *MLLT10* rs12770228, *CASP8* rs1045485, *XRCC1* rs1799782, *XRCC1* rs25487, *MTHFR* rs1801133, *MTHFR* rs1801131, *MTRR* rs1801394, *MTR* rs1805087, *GSTM1* null/present, and *GSTT1* null/present were analyzed ([Table 2](#t2-ott-10-1875){ref-type="table"}).

*MLLT10* rs12770228
-------------------

We first evaluated the association between rs12770228 of *MLLT10* and meningioma risk. As shown in [Figure 2A](#f2-ott-10-1875){ref-type="fig"} and [Table 3](#t3-ott-10-1875){ref-type="table"}, a fixed-effect model was used under the allele (A vs G), homozygote (AA vs GG) and recessive (AA vs GG+GA) models, due to low degree or no heterogeneity (heterogeneity, all *P*\>0.1, *I*^2^\<25%), whereas a random-effect model was applied for others. Pooled analysis data suggested that increased meningioma risk was detected under all genetic models ([Table 3](#t3-ott-10-1875){ref-type="table"}, test of association, all ORs \>1, *P*\<0.001). In addition, the existence of publication bias was excluded ([Figure 2B and C](#f2-ott-10-1875){ref-type="fig"}, [Table 4](#t4-ott-10-1875){ref-type="table"}, Begg's test, Egger's test, all *P*\>0.05). We also performed a sensitivity meta-analysis and found that the corresponding pooled OR value did not differ significantly from that of the overall meta-analysis ([Figure 2D](#f2-ott-10-1875){ref-type="fig"} for allele model; data not shown for other models). These results suggested that the *MLLT10* rs12770228 A/G polymorphism may be associated with increased meningioma risk.

*CASP8* rs1045485
-----------------

The association between *CASP8* rs1045485 and susceptibility to meningioma was then analyzed. As shown in [Table 3](#t3-ott-10-1875){ref-type="table"}, a fixed-effect model was utilized for the allele, homozygote, dominant, and recessive models (heterogeneity, all *P*\>0.1, *I*^2^\<25%), but not the heterozygote model ([Table 3](#t3-ott-10-1875){ref-type="table"}, *I*^2^=26.4%). The genetic association between the rs1045485 G/C allele frequency of *CASP8* and increased meningioma risk was obtained under the C vs G model (OR 1.14, 95% CI 0.94--1.4; *P*=0.181). In addition, we did not observe significantly increased meningioma risk in any genetic model ([Table 3](#t3-ott-10-1875){ref-type="table"}, test of association, all *P*\>0.05). No publication bias was observed under any model either ([Table 4](#t4-ott-10-1875){ref-type="table"}, Begg's test, Egger's test, all *P*\>0.05). Sensitivity meta-analyses further confirmed the results (data not shown). Therefore, the *CASP8* rs1045485 polymorphism seems not to be associated with meningioma risk.

*XRCC1* rs1799782 and rs25487
-----------------------------

Next, we conducted meta-analyses of the associations between *XRCC1* rs1799782 and rs25487 polymorphisms and meningioma risk. For *XRCC1* rs1799782, no or low heterogeneity was observed, and a fixed-effect model was thus used for all genetic models ([Table 3](#t3-ott-10-1875){ref-type="table"}, heterogeneity, all *P*\>0.1, *I*^2^\<25%), apart from the heterozygote model (*I*^2^=34.2%). The results of [Table 3](#t3-ott-10-1875){ref-type="table"} show that significant differences were observed under the heterozygote (OR 0.75, 95% CI 0.61--0.94; *P*=0.01), dominant (OR 0.82, 95% CI 0.7--0.97; *P*=0.018), and recessive models (OR 1.43, 95% CI 1.05--1.95; *P*=0.022), but not other models. Furthermore, subgroup analyses based on ethnicity were performed under all models. A similar change for increased meningioma risk was observed in the Asian population under the heterozygote, dominant, and recessive models ([Table 5](#t5-ott-10-1875){ref-type="table"}). Begg's test and Egger's test data excluded the presence of large publication bias ([Table 4](#t4-ott-10-1875){ref-type="table"}, Begg's test and Egger's test, all *P*\>0.05).

For *XRCC1* rs25487, a random-effect model was used under all genetic models ([Table 3](#t3-ott-10-1875){ref-type="table"}, heterogeneity, all *I*^2^\>25%). No significant difference and no publication bias were observed under any genetic models ([Table 3](#t3-ott-10-1875){ref-type="table"}, test of association, all *P*\>0.05; [Table 4](#t4-ott-10-1875){ref-type="table"}, Begg's test and Egger's test, all *P*\>0.05). Sensitivity meta-analyses further confirmed these results (data not shown). The data failed to provide strong evidence for an association between *XRCC1* rs1799782 or rs25487 polymorphisms and increased meningioma risk.

*MTHFR* rs1801133 and rs1801131
-------------------------------

As shown in [Table 3](#t3-ott-10-1875){ref-type="table"}, a random-effect model was used for *MTHFR* rs1801133 (heterogeneity, all *I*^2^\>25%), while a fixed-effect model was used for *MTHFR* rs1801131 (heterogeneity, all *P*\>0.1, *I*^2^=0%). No significant difference was observed for rs1801133 or rs1801131 under any genetic model ([Table 3](#t3-ott-10-1875){ref-type="table"}, test of association, all *P*\>0.05). No publication bias was observed under any models ([Table 4](#t4-ott-10-1875){ref-type="table"}, Begg's test and Egger's test, all *P*\>0.05), apart from the allele and homozygote models of rs1801133 ([Table 4](#t4-ott-10-1875){ref-type="table"}, Egger's test, *P*\<0.05). Subgroup analyses of ethnicity further showed a significant difference only for rs1801131 under the heterozygote (AC vs AA, OR 1.32, 95% CI 1.09--1.59; *P*=0.004) and dominant (AC+CC vs AA, OR 1.23, 95% CI 1.03--1.48; *P*=0.023) models of rs1801131 in the Caucasian population ([Table 5](#t5-ott-10-1875){ref-type="table"}), suggesting that the AC genotype of *MTHFR* rs1801131 might be associated with increased meningioma risk in the Caucasian population. Sensitivity meta-analyses further confirmed these results (data not shown).

*MTRR* rs1801394 and MTR rs1805087
----------------------------------

Fixed-effect models were used for *MTRR* rs1801394 and *MTR* rs1805087 ([Table 3](#t3-ott-10-1875){ref-type="table"}, heterogeneity, all *P*\>0.1, *I*^2^\<25%). Significantly increased meningioma risk was observed for *MTRR* rs1801394 under the allele (G vs A), homozygote (GG vs AA), dominant (AG+GG vs AA), and recessive (GG vs AA+AG) models ([Table 3](#t3-ott-10-1875){ref-type="table"}, test of association, all OR\>1, *P*\<0.05). Nevertheless, no increased meningioma risk was observed for *MTR* rs1805087 under any model ([Table 3](#t3-ott-10-1875){ref-type="table"}, test of association, all *P*\>0.05). Subgroup analyses further indicated that there was increased meningioma risk for *MTRR* rs1801394 under the allele, homozygote, and recessive models in the Asian population and the allele and homozygote models in the Caucasian population ([Table 5](#t5-ott-10-1875){ref-type="table"}, test of association, all *P*\<0.05). No publication bias was detected for *MTRR* rs1801394 or *MTR* rs1805087 under any model ([Table 4](#t4-ott-10-1875){ref-type="table"}, Begg's test and Egger's test, all *P*\>0.1). The results were further confirmed by sensitivity meta-analyses (data not shown). These data demonstrated that *MTRR* rs1801394, but not *MTR* rs1805087, is more likely to be linked to increased meningioma risk.

*GSTM1* and *GSTT1* null/present
--------------------------------

Finally, we investigated the genetic relationship between the null/present genotype of *GSTM1* and *GSTT1* and meningioma risk. A fixed model was used for *GSTM1* ([Figure 3A](#f3-ott-10-1875){ref-type="fig"}, heterogeneity, *P*=0.289, *I*^2^=20.1%), whereas a random model was used for *GSTT1* ([Figure 4A](#f4-ott-10-1875){ref-type="fig"}, heterogeneity, *P*=0.108, *I*^2^=50.6%). No increased or decreased meningioma risk was observed for the null genotype of *GSTM1* ([Figure 3A](#f3-ott-10-1875){ref-type="fig"}, test of association, *P*=0.73) or *GSTT1* ([Figure 4A](#f4-ott-10-1875){ref-type="fig"}, test of association, *P*=0.099). No publication bias was detected ([Figure 3B and C](#f3-ott-10-1875){ref-type="fig"}, [Figure 4B and C](#f4-ott-10-1875){ref-type="fig"}, Begg's test and Egger's test, all *P*\>0.05). Sensitivity meta-analyses ([Figures 3D](#f3-ott-10-1875){ref-type="fig"} and [4D](#f4-ott-10-1875){ref-type="fig"}) further confirmed the results. These results demonstrated that the polymorphisms of *GSTM1* and *GSTT1* may not be associated with meningioma risk.

Discussion
==========

In the present study, we performed an updated meta-analysis to investigate potential genetic variants associated with meningioma risk. Ten genetic variants of eight genes were targeted. These genes can be classified into five categories: 1) chromosomal rearrangement-associated gene, *MLLT10*; 2) apoptosis-associated gene, *CASP8*; 3) DNA repair-associated gene, *XRCC1*; 4) folate-metabolism genes, *MTHFR*, *MTRR*, and *MTR*; 5) and drug metabolism-related genes, *GSTM1* and *GSTT1*.

Folate metabolism-associated gene mutations have been reported to be associated with several diseases.[@b12-ott-10-1875],[@b40-ott-10-1875] The MTHFR protein, a kind of folate-metabolizing enzyme, is required for the methylation of homocysteine to methionine.[@b41-ott-10-1875]--[@b44-ott-10-1875] Both the *MTRR* and *MTR* genes are also indispensable for the folate metabolic pathway.[@b40-ott-10-1875] Polymorphisms of *MTHFR*, *MTRR*, and *MTR* have been reported to be linked to susceptibility to meningioma in certain populations. For example, *MTHFR* rs1801133 or MTRR rs1801394 was found to be associated with meningioma risk in the Chinese population.[@b20-ott-10-1875],[@b26-ott-10-1875] However, the role of *MTHFR* polymorphisms in the presence of meningioma is still conflicting. For instance, there was no significant genetic association between *MTHFR* rs1801133 and meningioma risk in the Turkish population.[@b28-ott-10-1875] The TT genotype of *MTHFR* rs1801133 may be related to the lower risk of meningioma in the Korean population.[@b39-ott-10-1875]

Ding et al conducted a meta-analysis of nine case-control studies, and found that the CT genotype of *MTHFR* rs1801133 might be linked to high meningioma risk in Caucasians.[@b13-ott-10-1875] Xu et al found that significantly increased meningioma risk was only observed under the TC vs CC model in a meta-analysis of four studies.[@b9-ott-10-1875] A meta-analysis by Zeng et al showed that the *MTRR* rs1801394 polymorphism (seven case-control studies), but not *MTR* rs1805087 (seven case-control studies), may be associated with meningioma risk in adults.[@b8-ott-10-1875] We removed data that did not meet the HWE, such as the rs1805087 data of Zhang et al,[@b20-ott-10-1875] and added data from case-control studies, such as the WHO grade III meningioma group.[@b21-ott-10-1875] As such, *MTHFR* rs1801133 (eleven case-control studies), *MTRR* rs1801394 (eight case-control studies) and *MTR* rs1805087 (seven case-control studies, all in the Caucasian population) were enrolled in the present updated meta-analysis. Our results indicated that *MTRR* rs1801394, but not *MTHFR* rs1801133 or *MTR* rs1805087, is likely to be associated with meningioma risk, and the AC genotype of *MTHFR* rs1801131 may confer high susceptibility to meningioma in the Caucasian population. The precise molecular mechanisms of *MTHFR* and *MTR* mutations in the incidence of meningioma remain unclear. Due to its close relationship with the synthesis, methylation, and repair of DNA, folate is essential for the production or maintenance of normal cells and the inhibition of tumor cells.[@b45-ott-10-1875]--[@b47-ott-10-1875] It is possible that the harmful mutation of *MTHFR* rs1801131 or *MTRR* rs1801394 confers susceptibility to meningioma via abnormal of enzyme activity and folate-involved DNA metabolism. More experiments are needed.

In addition to folate-metabolism genes, susceptibility loci of drug metabolism-related genes *GSTM1* and *GSTT1*, apoptosis-associated gene *CASP8*, DNA repair-associated gene *XRCC1*, and chromosomal rearrangement-associated gene *MLLT10* have also been reported in various clinical diseases.[@b48-ott-10-1875]--[@b52-ott-10-1875] For instance, *GSTM1* and *GSTT1* polymorphisms might be associated with renal cell carcinoma risk or treatment outcomes of breast cancer.[@b48-ott-10-1875],[@b49-ott-10-1875] *XRCC1* polymorphisms are likely linked to the risk of lung cancer in Caucasian population.[@b51-ott-10-1875] Cryptic *XPO1*--*MLLT10* translocation was related to homeobox A-locus deregulation in T-cell acute lymphoblastic leukemia.[@b52-ott-10-1875] Here, the results of our meta-analysis under all genetic models showed that the rs12770228 polymorphism of *MLLT10* was significantly associated with increased meningioma risk. However, no strong association between *GSTM1*, *GSTT1*, *CASP8*, *XRCC1* and meningioma susceptibility was obtained. The negative associations between *GSTM1* and *GSTT1* null/present and meningioma risk were partly in line with previous results on the role of *GSTM1* and *GSTT1* polymorphisms in brain-tumor risk.[@b10-ott-10-1875],[@b11-ott-10-1875] In spite of this, the possibility of potential roles of these polymorphisms in inherited meningioma risk still cannot be ruled out.

Limitations
-----------

Although the strict exclusion and inclusion criteria were utilized to select eligible studies, several limitations in our meta-analysis must be acknowledged. We tried our best to search the electronic databases for relevant articles, and analyzed the potential meningioma-associated genetic variants via meta-analysis. Multiple genes, such as *CDKN2* and *PON1*, were initially retrieved.[@b23-ott-10-1875],[@b53-ott-10-1875] However, genes for which the number of case-control studies on specific variants was fewer than three were removed. As such, only eight genes were collected. We admit that there was a very limited number of included studies and very small sample size in case-control studies for our meta-analysis. Considering the limitation of small study numbers on the evaluation efficiency of publication bias via Begg's test,[@b16-ott-10-1875] there is still the potential of publication bias, which may have affected our conclusions.

Even though the Mantel--Haenszel statistics under the random-effect model and sensitivity analyses were used for between-study heterogeneity, there were small sample sizes, and other unpublished or unavailable data are still needed. SNPs, disease characteristics, and other environmental effect modifiers contribute to meningioma risk. Several factors, such as ionizing radiation, estrogen level, and traumatic brain injury, might be involved in the complicated etiology or pathology of meningiomas.[@b54-ott-10-1875]--[@b56-ott-10-1875] Unfortunately, only stratified analysis according to ethnic background was performed for *XRCC1* rs1799782, *MTHFR* rs1801133, rs1801131, and *MTRR* rs1801394. More subgroup analysis based on more factors (eg, sex, disease type, or other clinical characteristics) were needed for a proper judgment of the genetic association between the measured variants and meningioma risk.

Very limited genome-wide association study (GWAS) data, genome-wide SNP linkage-disequilibrium mapping, or exome sequencing was obtained.[@b33-ott-10-1875],[@b57-ott-10-1875],[@b58-ott-10-1875] We found that the *MLLT10* gene was identified from the GWAS data on meningioma risk.[@b32-ott-10-1875],[@b33-ott-10-1875] However, the positive association of *MTRR* rs1801394 and *MTHFR* rs1801131 failed to obtain the support of GWAS data. Further investigations with more subjects are warranted to confirm the role of *CASP8*, *XRCC1*, *MTHFR*, *MTRR*, *MTR*, *GSTM1*, *GSTT1*, and other genes identified from high-throughput analysis, such as *PIAS2* and *KATNAL2*.

Conclusion
==========

Our updated meta-analysis concluded that *MLLT10* rs12770228 and *MTRR* rs1801394 polymorphisms may be meningioma risk factors. Also, the AC genotype of *MTHFR* rs1801131 appears to be associated with increased susceptibility to meningioma in the Caucasian population.
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![Meta-analysis of the association between the *MLLT10* polymorphism and meningioma risk under the allele model.\
**Notes:** (**A**) Forest plot analysis; (**B**) Begg's test with size graph symbol by weights; (**C**) Egger's test with size graph symbol by weights; and (**D**) sensitivity meta-analysis. Weights are from fixed-effect analysis. The "given name study is omitted" was produced by the STAT12.0 software. It means the given name studies were omitted, and the meta-analysis data by other studies were showed.\
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![Meta-analysis of the association between the *GSTM1* polymorphism and meningioma risk.\
**Notes:** (**A**) Forest plot analysis; (**B**) Begg's test with size graph symbol by weights; (**C**) Egger's test with size graph symbol by weights; and (**D**) sensitivity meta-analysis. Weights are from fixed-effect analysis. The "given name study is omitted" was produced by the STAT12.0 software. It means the given name studies were omitted, and the meta-analysis data by other studies were showed.\
**Abbreviations:** OR, odds ratio; CI, confidence interval; SE, standard error.](ott-10-1875Fig3){#f3-ott-10-1875}

![Meta-analysis of the association between the *GSTT1* polymorphism and meningioma risk.\
**Notes:** (**A**) Forest plot analysis; (**B**) Begg's test with size graph symbol by weights; (**C**) Egger's test with size graph symbol by weights; and (**D**) sensitivity meta-analysis. Weights are from random-effect analysis. The "given name study is omitted" was produced by the STAT12.0 software. It means the given name studies were omitted, and the meta-analysis data by other studies were showed.\
**Abbreviations:** OR, odds ratio; CI, confidence interval; SE, standard error.](ott-10-1875Fig4){#f4-ott-10-1875}

###### 

Characteristics of studies included in the meta-analysis

  Study                                        Year   Country/region    Ethnicity   Gene       SNP            Case                                                                                           Disease group           Control                                                                                         Source of controls   HWE, *P*-value   Genotyping methods                            NOS score
  -------------------------------------------- ------ ----------------- ----------- ---------- -------------- ---------------------------------------------------------------------------------------------- ----------------------- ----------------------------------------------------------------------------------------------- -------------------- ---------------- --------------------------------------------- -----------
  Ahn et al[@b39-ott-10-1875]                  2002   South Korea       Asian       *MTHFR*    rs1801133      16/13/3                                                                                        Meningioma              91/129/34                                                                                       PB                   0.27             PCR-RFLP                                      7
  Bethke et al[@b38-ott-10-1875]               2009   Finland           Caucasian   *CASP8*    rs1045485      60/16/0                                                                                        Meningioma              65/7/0                                                                                          PB                   0.66             Illumina customized GoldenGate array          7
                                                      Denmark           Caucasian   *CASP8*    rs1045485      81/20/0                                                                                                                84/23/1                                                                                         PB                   0.67                                                           
                                                      UK -- South       Caucasian   *CASP8*    rs1045485      92/21/6                                                                                                                93/24/1                                                                                         PB                   0.68                                                           
                                                      UK -- North       Caucasian   *CASP8*    rs1045485      128/37/2                                                                                                               133/29/4                                                                                        PB                   0.13                                                           
                                                      Sweden            Caucasian   *CASP8*    rs1045485      115/27/2                                                                                                               115/27/1                                                                                        PB                   0.67                                                           
  Bethke et al[@b37-ott-10-1875]               2008   UK -- North       Caucasian   *MTHFR*    rs1801131      80/73/20                                                                                       Meningioma              94/64/17                                                                                        PB                   0.22             Illumina GoldenGate array                     7
                                                      UK -- North       Caucasian   *MTHFR*    rs1801133      57/98/19                                                                                                               73/78/24                                                                                        PB                   0.66                                                           
                                                      UK -- North       Caucasian   *MTRR*     rs1801394      54/83/37                                                                                                               74/78/23                                                                                        PB                   0.73                                                           
                                                      UK -- North       Caucasian   *MTR*      rs1805087      113/54/7                                                                                                               106/60/8                                                                                        PB                   0.89                                                           
                                                      UK -- Southeast   Caucasian   *MTHFR*    rs1801131      54/59/8                                                                                                                62/48/13                                                                                        PB                   0.42                                                           
                                                      UK -- Southeast   Caucasian   *MTHFR*    rs1801133      50/57/14                                                                                                               48/60/15                                                                                        PB                   0.57                                                           
                                                      UK -- Southeast   Caucasian   *MTRR*     rs1801394      41/57/23                                                                                                               39/59/25                                                                                        PB                   0.76                                                           
                                                      UK -- Southeast   Caucasian   *MTR*      rs1805087      77/39/5                                                                                                                75/42/6                                                                                         PB                   0.97                                                           
                                                      Sweden            Caucasian   *MTHFR*    rs1801131      61/77/11                                                                                                               64/66/19                                                                                        PB                   0.76                                                           
                                                      Sweden            Caucasian   *MTHFR*    rs1801133      64/68/17                                                                                                               82/57/10                                                                                        PB                   0.98                                                           
                                                      Sweden            Caucasian   *MTRR*     rs1801394      39/84/26                                                                                                               53/74/22                                                                                        PB                   0.64                                                           
                                                      Sweden            Caucasian   *MTR*      rs1805087      98/45/6                                                                                                                94/51/4                                                                                         PB                   0.34                                                           
                                                      Denmark           Caucasian   *MTHFR*    rs1801131      44/57/9                                                                                                                53/43/17                                                                                        PB                   0.1                                                            
                                                      Denmark           Caucasian   *MTHFR*    rs1801133      45/55/10                                                                                                               56/45/12                                                                                        PB                   0.52                                                           
                                                      Denmark           Caucasian   *MTRR*     rs1801394      41/47/22                                                                                                               40/55/18                                                                                        PB                   0.90                                                           
                                                      Denmark           Caucasian   *MTR*      rs1805087      73/33/4                                                                                                                70/40/3                                                                                         PB                   0.33                                                           
                                                      Finland           Caucasian   *MTHFR*    rs1801131      38/31/8                                                                                                                37/32/8                                                                                         PB                   0.78                                                           
                                                      Finland           Caucasian   *MTHFR*    rs1801133      46/26/5                                                                                                                47/25/5                                                                                         PB                   0.51                                                           
                                                      Finland           Caucasian   *MTRR*     rs1801394      26/37/14                                                                                                               30/33/14                                                                                        PB                   0.36                                                           
                                                      Finland           Caucasian   *MTR*      rs1805087      50/24/3                                                                                                                56/17/4                                                                                         PB                   0.1                                                            
  Cacina et al[@b36-ott-10-1875]               2015   Turkey            Caucasian   *CASP8*    rs1045485      28/8/3                                                                                         Meningioma              66/42/6                                                                                         PB                   0.84             PCR-RFLP                                      7
  Cengiz et al[@b35-ott-10-1875]               2008   Turkey            Caucasian   *XRCC1*    rs25487        25/41/5                                                                                        Meningioma              43/41/3                                                                                         PB                   0.07             PCR-RFLP                                      8
  De Roos et al[@b34-ott-10-1875]              2003   US                Caucasian   *GSTM1*    Present/null   85[b](#tfn3-ott-10-1875){ref-type="table-fn"}/84[c](#tfn4-ott-10-1875){ref-type="table-fn"}    Meningioma              254[b](#tfn3-ott-10-1875){ref-type="table-fn"}/321[c](#tfn4-ott-10-1875){ref-type="table-fn"}   HB                   --               PCR                                           7
                                                                                    *GSTT1*    Present/null   121[b](#tfn3-ott-10-1875){ref-type="table-fn"}/38[c](#tfn4-ott-10-1875){ref-type="table-fn"}                           445[b](#tfn3-ott-10-1875){ref-type="table-fn"}/100[c](#tfn4-ott-10-1875){ref-type="table-fn"}   HB                   --                                                             
  Dobbins et al[@b33-ott-10-1875]              2011   Germany           Caucasian   *MLLT10*   rs12770228     309/426/123                                                                                    Meningioma              328/302/74                                                                                      PB                   0.72             [a](#tfn2-ott-10-1875){ref-type="table-fn"}   7
                                                      UK                Caucasian   *MLLT10*   rs12770228     144/187/73                                                                                                             361/321/76                                                                                      PB                   0.71                                                           
                                                      Scandinavia       Caucasian   *MLLT10*   rs12770228     145/158/47                                                                                                             463/424/91                                                                                      PB                   0.67                                                           
  Egan et al[@b32-ott-10-1875]                 2015   US                Caucasian   *MLLT10*   rs12770228     111/111/46                                                                                     Meningioma              287/267/74                                                                                      PB                   0.33             TaqMan assays                                 7
  Elexpuru-Camiruaga et al[@b31-ott-10-1875]   1995   UK                Caucasian   *GSTM1*    Present/null   22[b](#tfn3-ott-10-1875){ref-type="table-fn"}/27[c](#tfn4-ott-10-1875){ref-type="table-fn"}    Meningioma              262[b](#tfn3-ott-10-1875){ref-type="table-fn"}/315[c](#tfn4-ott-10-1875){ref-type="table-fn"}   HB                   --               PCR                                           7
                                                      UK                Caucasian   *GSTT1*    Present/null   26[b](#tfn3-ott-10-1875){ref-type="table-fn"}/21[c](#tfn4-ott-10-1875){ref-type="table-fn"}                            403[b](#tfn3-ott-10-1875){ref-type="table-fn"}/91[c](#tfn4-ott-10-1875){ref-type="table-fn"}    HB                   --                                                             
  Huang et al[@b30-ott-10-1875]                2012   China             Asian       *XRCC1*    rs1799782      100/80/25                                                                                      Meningioma              95/102/21                                                                                       PB                   0.39             Snapshot multiplex                            8
                                                      China             Asian       *XRCC1*    rs1799782      53/24/11                                                                                       \<50 years old          41/51/12                                                                                        PB                   0.52                                                           
                                                      China             Asian       *XRCC1*    rs1799782      47/56/14                                                                                       ≥50 years old           54/51/9                                                                                         PB                   0.52                                                           
                                                      China             Asian       *XRCC1*    rs1799782      27/20/7                                                                                        Male                    29/36/9                                                                                         PB                   0.67                                                           
                                                      China             Asian       *XRCC1*    rs1799782      73/60/18                                                                                       Female                  66/66/12                                                                                        PB                   0.42                                                           
  Huang et al[@b29-ott-10-1875]                2015   China             Asian       *XRCC1*    rs1799782      63/41/20                                                                                       Skull-base meningioma   95/102/21                                                                                       PB                   0.39             Snapshot multiplex                            8
  Kafadar et al[@b28-ott-10-1875]              2006   Turkey            Caucasian   *MTHFR*    rs1801133      20/12/3                                                                                        Meningioma              53/38/7                                                                                         PB                   0.96             PCR-RFLP                                      9
  Kiuru et al[@b27-ott-10-1875]                2008   Mixed             Caucasian   *XRCC1*    rs1799782      469/50/2                                                                                       Meningioma              1,377/177/2                                                                                     PB                   0.13             PCR-RFLP                                      9
                                                      Mixed             Caucasian   *XRCC1*    rs25487        212/233/74                                                                                                             645/728/176                                                                                     PB                   0.17                                                           
  Li et al[@b26-ott-10-1875]                   2013   China             Asian       *MTHFR*    rs1801133      101/147/69                                                                                     Meningioma              159/129/32                                                                                      PB                   0.44             PCR-RFLP                                      9
                                                      China             Asian       *MTHFR*    rs1801131      205/96/16                                                                                                              201/98/21                                                                                       PB                   0.06                                                           
  Pinarbasi et al[@b25-ott-10-1875]            2005   Turkey            Caucasian   *GSTM1*    Present/null   12[b](#tfn3-ott-10-1875){ref-type="table-fn"}/11[c](#tfn4-ott-10-1875){ref-type="table-fn"}    Meningioma              116[b](#tfn3-ott-10-1875){ref-type="table-fn"}/37[c](#tfn4-ott-10-1875){ref-type="table-fn"}    HB                   --               PCR                                           7
                                                      Turkey            Caucasian   *GSTT1*    Present/null   17[b](#tfn3-ott-10-1875){ref-type="table-fn"}/6[c](#tfn4-ott-10-1875){ref-type="table-fn"}                             122[b](#tfn3-ott-10-1875){ref-type="table-fn"}/31[c](#tfn4-ott-10-1875){ref-type="table-fn"}    HB                   --                                                             
  Rajaraman et al[@b24-ott-10-1875]            2010   US                Caucasian   *XRCC1*    rs1799782      104/18/0                                                                                       Meningioma              394/73/1                                                                                        HB                   0.21             TaqMan assay                                  7
                                                      US                Caucasian   *XRCC1*    rs25487        56/62/14                                                                                                               205/201/72                                                                                      HB                   0.05                                                           
  Rajaraman et al[@b23-ott-10-1875]            2007   US                Caucasian   *CASP8*    rs1045485      117/38/5                                                                                       Meningioma              426/118/6                                                                                       HB                   0.87             Medium-throughput TaqMan assay                7
  Schwartzbaum et al[@b22-ott-10-1875]         2007   Mixed             Caucasian   *GSTM1*    Present/null   68[b](#tfn3-ott-10-1875){ref-type="table-fn"}/108[c](#tfn4-ott-10-1875){ref-type="table-fn"}   Meningioma              193[b](#tfn3-ott-10-1875){ref-type="table-fn"}/237[c](#tfn4-ott-10-1875){ref-type="table-fn"}   PB                   --               PCR                                           8
                                                      Mixed             Caucasian   *GSTT1*    Present/null   149[b](#tfn3-ott-10-1875){ref-type="table-fn"}/27[c](#tfn4-ott-10-1875){ref-type="table-fn"}                           362[b](#tfn3-ott-10-1875){ref-type="table-fn"}/68[c](#tfn4-ott-10-1875){ref-type="table-fn"}    PB                   --                                                             
  Semmler et al[@b21-ott-10-1875]              2008   Germany           Caucasian   *MTHFR*    rs1801133      131/133/26                                                                                     Meningioma              132/135/20                                                                                      PB                   0.06             PCR-RFLP                                      8
                                                      Germany           Caucasian   *MTHFR*    rs1801131      116/142/32                                                                                     Meningioma              132/123/32                                                                                      PB                   0.68                                                           
                                                      Germany           Caucasian   *MTR*      rs1805087      197/81/12                                                                                      Meningioma              184/92/11                                                                                       PB                   0.91                                                           
                                                      Germany           Caucasian   *MTHFR*    rs1801133      10/7/1                                                                                         WHO grade III           132/135/20                                                                                      PB                   0.91                                                           
                                                      Germany           Caucasian   *MTHFR*    rs1801131      7/10/1                                                                                         WHO grade III           132/123/32                                                                                      PB                   0.91                                                           
                                                      Germany           Caucasian   *MTR*      rs1805087      18/0/0                                                                                         WHO grade III           184/92/11                                                                                       PB                   0.91                                                           
  Zhang et al[@b20-ott-10-1875]                2013   China             Asian       *MTHFR*    rs1801131      184/157/50                                                                                     WHO grade I             289/245/66                                                                                      PB                   0.2              PCR-RFLP                                      8
                                                      China             Asian       *MTRR*     rs1801394      135/176/80                                                                                     WHO grade I             225/282/93                                                                                      PB                   0.77                                                           
                                                      China             Asian       *MTHFR*    rs1801131      79/67/21                                                                                       WHO grade II            289/245/66                                                                                      PB                   0.2                                                            
                                                      China             Asian       *MTRR*     rs1801394      59/74/34                                                                                       WHO grade II            225/282/93                                                                                      PB                   0.77                                                           
                                                      China             Asian       *MTHFR*    rs1801131      20/17/5                                                                                        WHO grade III           289/245/66                                                                                      PB                   0.2                                                            
                                                      China             Asian       *MTRR*     rs1801394      15/19/8                                                                                        WHO grade III           225/282/93                                                                                      PB                   0.77                                                           

**Notes:** M, major allele; m, minor allele.

Illumina Infinium HD human 662 quad or OmniExpress BeadChip, competitive allele-specific KASP chemistry;

number of samples with *GSTM1* or *GSTT1* null genotype;

number of samples with *GSTM1* or *GSTT1* null/present genotype. '--' indicates not available.

**Abbreviations:** SNP, single-nucleotide polymorphism; HWE, Hardy--Weinberg Equilibrium; NOS, Newcastle--Ottawa Scale; PB, population-based; PCR-RFLP, polymerase chain reaction--restriction fragment-length polymorphism; HB, hospital-based; WHO, World Health Organization.

###### 

Genes and SNPs included in the meta-analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene       Chromosome    SNP          Sequence                                  Global MAF        Variants       Description
  ---------- ------------- ------------ ----------------------------------------- ----------------- -------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  *MLLT10*   10:21494705   rs12770228   CTTTCGCTTGCGGTTTGCAACCCCT\                A =0.156/781      C895T          Transcription factor and partner gene involved in several chromosomal rearrangements
                                        \[[A/G]{.ul}\]GGGTGGGTCTGACCCCGCGCGGCAC                                    

  *CASP8*    2:201284866   rs1045485    GCTTCATTTTGAGATCAAGCCCCAC\                C =0.0527/264     D302H          Apoptosis-related cysteine peptidase
                                        \[C/G\]ATGACTGCACAGTAGAGCAAATCTA                                           

  *XRCC1*    19:43553422   rs1799782    GAGGCCGGGGGCTCTCTTCTTCAGC\                A =0.1238/620     R194W          DNA repair of single-strand breaks and base excision
                                        \[[C/T]{.ul}\]GGATCAACAAGACATCCCCAGGTGA                                    

             19:43551574   rs25487      CGCATGCGTCGGCGGCTGCCCTCCC\                T =0.2604/1,304   Q399R          
                                        \[[A/G]{.ul}\]GAGGTAAGGCCTCACACGCCAACCC                                    

  *MTHFR*    1:11796321    rs1801133    TTGAAGGAGAAGGTGTCTGCGGGAG\                A =0.2454/1,229   C677T          Catalyzes the conversion of 5,10-methylenetetrahydrofolate to
                                        \[[C/T]{.ul}\]CGATTTCATCATCACGCAGCTTTTC                                    

             1:11794419    rs1801131    TGGGGGGAGGAGCTGACCAGTGAAG\                G =0.2494/1,249   A1298C         5-methyltetrahydrofolate, and a cosubstrate for homocysteine remethylation to methionine
                                        \[[A/C]{.ul}\]AAGTGTCTTTGAAGTCTTCGTTCTT                                    

  *MTRR*     5:7870860     rs1801394    AGGCAAAGGCCATCGCAGAAGAAAT\                G =0.3642/1,824   A66G           Involved in the reductive regeneration of cobalamin cofactor required for the maintenance of methionine synthase in a functional state
                                        \[[A/G]{.ul}\]TGTGAGCAAGCTGTGGTACATGGAT                                    

  *MTR*      1:236885200   rs1805087    GAAGAATATGAAGATATTAGACAGG\                G =0.2183/1,093   A2756G         Cobalamin-dependent methionine synthase, catalyzes the final step in methionine biosynthesis
                                        \[[A/G]{.ul}\]CCATTATGAGTCTCTCAAGGTAAGT                                    

  *GSTM1*    --            --           --                                        --                Null/present   Member of GST family that conjugates with glutathione and functions in the detoxification of carcinogens, environmental toxins and products of oxidative stress

  *GSTT1*    --            --           --                                        --                Null/present   Member of GST family that catalyzes the conjugation of reduced glutathione to a variety of electrophilic and hydrophobic compounds
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** '--' indicates not available.

**Abbreviations:** SNPs, single-nucleotide polymorphisms; MAF, minor allele frequency; GST, glutathione S-transferase; A, adenine; G, guanine; C, cytosine; T, thymine.

###### 

Pooled analysis of the associations between *MLLT10*, *CASP8*, *XRCC1*, *MTHFR*, *MTRR*, and *MTR* polymorphisms and meningioma risk

  Gene       SNP          Comparison    Number of studies   Sample size   Test of association   Heterogeneity       Model                    
  ---------- ------------ ------------- ------------------- ------------- --------------------- ------------------- --------- ------ ------- ---
  *MLLT10*   rs12770228   A vs G        4                   1,880         3,068                 1.36 (1.24--1.48)   \<0.001   16.6   0.309   F
                          AA vs GG      4                   1,880         3,068                 1.84 (1.53--2.23)   \<0.001   0      0.438   F
                          GA vs GG      4                   1,880         3,068                 1.32 (1.13--1.54)   \<0.001   27.7   0.246   R
                          GA+AA vs GG   4                   1,880         3,068                 1.42 (1.23--1.64)   \<0.001   28.7   0.24    R
                          AA vs GG+GA   4                   1,880         3,068                 1.36 (1.24--1.48)   \<0.001   0      0.552   F
  *CASP8*    rs1045485    C vs G        7                   806           1,271                 1.14 (0.94--1.4)    0.181     2.6    0.406   F
                          CC vs GG      6                   730           1,199                 1.67 (0.86--3.26)   0.129     5.5    0.382   F
                          GC vs GG      7                   806           1,271                 1.06 (0.8--1.4)     0.687     26.4   0.227   R
                          GC+CC vs GG   7                   806           1,271                 1.11 (0.89--1.39)   0.181     14.7   0.318   F
                          CC vs GG+GC   6                   730           1,199                 1.14 (0.94--1.4)    0.102     3.6    0.393   F
  *XRCC1*    rs1799782    T vs C        8                   1,382         2,896                 0.94 (0.82--1.07)   0.327     0      0.469   F
                          TT vs CC      8                   1,382         2,896                 1.22 (0.89--1.69)   0.219     0      0.83    F
                          CT vs CC      8                   1,382         2,896                 0.75 (0.61--0.94)   0.010     34.2   0.155   R
                          CT+TT vs CC   8                   1,382         2,896                 0.82 (0.7--0.97)    0.018     23.8   0.24    F
                          TT vs CC+CT   8                   1,382         2,896                 1.43 (1.05--1.95)   0.022     0      0.969   F
  *XRCC1*    rs25487      A vs G        3                   722           2,114                 1.08 (0.89--1.31)   0.440     37     0.205   R
                          AA vs GG      3                   722           2,114                 1.14 (0.67--1.95)   0.632     49.3   0.139   R
                          GA vs GG      3                   722           2,114                 1.09 (0.85--1.4)    0.495     27.8   0.25    R
                          GA+AA vs GG   3                   722           2,114                 1.1 (0.87--1.39)    0.429     25.3   0.262   R
                          AA vs GG+GA   3                   722           2,114                 1.09 (0.63--1.86)   0.766     54.2   0.112   R
  *MTHFR*    rs1801133    T vs C        10                  1,323         1,883                 1.14 (0.93--1.39)   0.222     64.2   0.003   R
                          TT vs CC      10                  1,323         1,883                 1.31 (0.87--1.98)   0.201     52     0.027   R
                          CT vs CC      10                  1,323         1,883                 1.19 (0.95--1.49)   0.132     43.8   0.066   R
                          CT+TT vs CC   10                  1,323         1,883                 1.19 (0.92--1.53)   0.180     58.9   0.009   R
                          TT vs CC+CT   10                  1,323         1,883                 1.22 (0.87--1.71)   0.239     36.6   0.115   R
  *MTHFR*    rs1801131    C vs A        11                  1,855         3,331                 1.05 (0.95--1.15)   0.335     0      0.97    F
                          CC vs AA      11                  1,855         3,331                 1.01 (0.82--1.24)   0.597     0      0.829   F
                          AC vs AA      11                  1,855         3,331                 1.13 (0.99--1.29)   0.060     0      0.793   F
                          AC+CC vs AA   11                  1,855         3,331                 1.11 (0.98--1.25)   0.108     0      0.935   F
                          CC vs AA+AC   11                  1,855         3,331                 0.94 (0.77--1.15)   0.574     0      0.594   F
  *MTRR*     rs1801394    G vs A        8                   1,231         2,437                 1.18 (1.06--1.31)   0.002     0      0.682   F
                          GG vs AA      8                   1,231         2,437                 1.4 (1.14--1.73)    0.002     0      0.756   F
                          AG vs AA      8                   1,231         2,437                 1.1 (0.93--1.3)     0.250     0      0.67    F
                          AG+GG vs AA   8                   1,231         2,437                 1.18 (1.01--1.37)   0.036     0      0.622   F
                          GG vs AA+AG   8                   1,231         2,437                 1.33 (1.1--1.61)    0.003     0      0.883   F
  *MTR*      rs1805087    G vs A        7                   939           1,210                 0.89 (0.75--1.04)   0.140     0      0.51    F
                          GG vs AA      7                   939           1,210                 0.96 (0.6--1.53)    0.867     0      0.985   F
                          AG vs AA      7                   939           1,210                 0.84 (0.69--1.02)   0.074     10.4   0.35    F
                          AG+GG vs AA   7                   939           1,210                 0.85 (0.7--1.02)    0.084     5.7    0.384   F
                          GG vs AA+AG   7                   939           1,210                 1.02 (0.64--1.61)   0.946     0      0.986   F

**Abbreviations:** SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval; F, fixed; R, random; A, adenine; G, guanine; C, cytosine; T, thymine.

###### 

Begg's test and Egger's test data

  Gene       SNP          Comparison    Begg's test   Egger's test           
  ---------- ------------ ------------- ------------- -------------- ------- -------
  *MLLT10*   rs12770228   A vs G        0.34          0.734          −0.59   0.613
                          AA vs GG      1.02          0.308          −0.32   0.778
                          GA vs GG      1.02          0.308          −2.02   0.18
                          GA+AA vs GG   0.34          0.734          −1.24   0.341
                          AA vs GG+GA   0.34          0.734          0.27    0.814
  *CASP8*    rs1045485    C vs G        0.6           0.548          −0.17   0.87
                          CC vs GG      0.38          0.707          −0.61   0.572
                          GC vs GG      0.6           0.548          −0.4    0.708
                          GC+CC vs GG   0.90          0.368          −0.31   0.77
                          CC vs GG+GC   0.38          0.707          −0.64   0.56
  *XRCC1*    rs1799782    T vs C        0.12          0.902          −0.71   0.506
                          TT vs CC      0.37          0.711          0.36    0.731
                          CT vs CC      0.37          0.711          −0.79   0.46
                          CT+TT vs CC   0.62          0.536          −0.6    0.569
                          TT vs CC+CT   −0.12         1              0.28    0.792
  *XRCC1*    rs25487      A vs G        0             1              0.35    0.784
                          AA vs GG      0             1              0.07    0.955
                          GA vs GG      1.04          0.296          4.08    0.153
                          GA+AA vs GG   1.04          0.296          1.3     0.418
                          AA vs GG+GA   0             1              −0.16   0.897
  *MTHFR*    rs1801133    T vs C        1.43          0.152          −2.33   0.048
                          TT vs CC      0.54          0.592          −2.51   0.036
                          CT vs CC      1.61          0.107          −1.88   0.097
                          CT+TT vs CC   1.43          0.152          −2.23   0.056
                          TT vs CC+CT   0.54          0.592          −1.96   0.086
  *MTHFR*    rs1801131    C vs A        1.09          0.276          −0.59   0.571
                          CC vs AA      1.09          0.276          −2.14   0.061
                          AC vs AA      0.93          0.35           1.45    0.181
                          AC+CC vs AA   0.47          0.64           0.92    0.38
                          CC vs AA+AC   1.4           0.161          −2.37   0.042
  *MTRR*     rs1801394    G vs A        1.11          0.266          −0.55   0.605
                          GG vs AA      1.11          0.266          −0.64   0.544
                          AG vs AA      −0.12         1              0.33    0.753
                          AG+GG vs AA   −0.12         1              0.01    0.99
                          GG vs AA+AG   1.61          0.108          −1.21   0.272
  *MTR*      rs1805087    G vs A        0             1              −1.55   0.183
                          GG vs AA      0.3           0.764          −0.73   0.497
                          AG vs AA      0.3           0.764          −0.95   0.385
                          AG+GG vs AA   0.3           0.764          −1.21   0.28
                          GG vs AA+AG   0.3           0.764          −0.46   0.662

**Abbreviations:** SNP, single-nucleotide polymorphism; A, adenine; G, guanine; C, cytosine; T, thymine.

###### 

Subgroup analysis of the association between *XRCC1*, *MTHFR*, and *MTRR* polymorphisms and meningioma risk

  Comparison      *XRCC1* rs1799782   *MTHFR* rs1801133   *MTHFR* rs1801131   *MTRR* rs1801394                                          
  --------------- ------------------- ------------------- ------------------- ------------------ ------------ ------------ ------------ ------------
  m vs M                                                                                                                                
   Studies, n     6                   2                   2                   8                  4            7            3            5
   Case-control   739/872             643/2,024           349/574             974/1,309          917/2,120    938/1,211    600/1,800    631/637
   OR             0.95                0.89                1.19                1.11               1.02         1.07         1.17         1.19
   95% CI         0.82--1.1           0.68--1.17          0.42--3.22          0.97--1.27         0.9--1.16    0.94--1.23   1.01--1.34   1.02--1.4
   *P*-value      0.511               0.408               0.775               0.129              0.73         0.301        0.032        0.03
  mm vs MM                                                                                                                              
   Studies, n     6                   2                   2                   8                  4            7            3            5
   Case-control   739/872             643/2,024           349/574             974/1,309          917/2,120    938/1,211    600/1,800    631/637
   OR             1.2                 2.3                 1.44                1.18               1.08         0.92         1.41         1.4
   95% CI         0.86--1.66          0.45--11.8          0.22--9.34          0.86--1.62         0.81--1.44   0.68--1.26   1.06--1.86   1.01--1.94
   *P*-value      0.283               0.32                0.703               0.302              0.592        0.618        0.016        0.04
  Mm vs MM                                                                                                                              
   Studies, n     6                   2                   2                   8                  4            7            3            5
   Case-control   739/872             643/2,024           349/574             974/1,309          917/2,120    938/1,211    600/1,800    631/637
   OR             0.7                 0.86                1.07                1.17               0.99         1.32         1.02         1.21
   95% CI         0.52--0.95          0.64--1.14          0.35--3.26          0.97--1.42         0.83--1.19   1.09--1.59   0.82--1.27   0.94--1.54
   *P*-value      0.022               0.282               0.902               0.11               0.931        0.004        0.827        0.136
  Mm+mm vs MM                                                                                                                           
   Studies, n     6                   2                   2                   8                  4            7            3            5
   Case-control   739/872             643/2,024           349/574             974/1,309          917/2,120    938/1,211    600/1,800    631/637
   OR             0.8                 0.87                1.13                1.17               1.01         1.23         1.12         1.26
   95% CI         0.66--0.97          0.66--1.15          0.31--4.17          0.98--1.4          0.85--1.19   1.03--1.48   0.91--1.37   1--1.59
   *P*-value      0.026               0.331               0.85                0.08               0.932        0.023        0.277        0.052
  mm vs MM+Mm                                                                                                                           
   Studies, n     6                   2                   2                   8                  4            7            3            5
   Case-control   739/872             643/2,024           349/574             974/1,309          917/2,120    938/1,211    600/1,800    631/637
   OR             1.41                2.33                1.48                1.07               1.09         0.8          1.39         1.26
   95% CI         1.03--1.93          0.45--11.99         0.42--5.25          0.79--1.44         0.83--1.43   0.6--1.08    1.08--1.78   0.94--1.68
   *P*-value      0.031               0.31                0.547               0.674              0.552        0.146        0.01         0.121

**Notes:** M, major allele; m, minor allele.

**Abbreviations:** OR, odds ratio; CI, confidence interval.
